Long Term Forecasts. LifeScan shall each month provide ENACT with ------------------- a non-binding forecast of the anticipated quantity of Product and Services to be contracted with Supplier over the next twelve (12) month period. Thereafter, each month during the term of this Agreement, LifeScan will use reasonable efforts to provide ENACT a rolling twelve (12) month forecast of its usage of Products and Services. Such forecast shall specify LifeScan's reasonable estimates of the anticipated quantity of Products and Services required weekly during the first three (3) months and monthly during the remaining nine (9) months.
Long Term Forecasts. 22 3.4 Long-Term Forecasts Nonbinding............................22 3.5 Short-Term Forecasts......................................23 3.6
Long Term Forecasts. Not less than six months prior to the actual date of First Commercial Sale of Licensed Products in the Territory (the "Startup Date"), Synthelabo shall provide PRAECIS with a non-binding forecast (a "Long-Term Forecast") of its total good-faith estimate of its requirements for Licensed Products during the first three annual periods following the Startup Date, with such projected requirements to be broken down on a quarter-by-quarter basis for each such annual period. Not later than the first December 1 following the Startup Date and, thereafter, on each anniversary of such date, Synthelabo shall provide PRAECIS with a revised Long-Term Forecast covering the three calendar years following the year in which such revised Long-Term Forecast is provided, with such projected requirements to be broken down on a quarter-by-quarter basis for each such calendar year.
Long Term Forecasts. The forecast to be provided under Section 5.1.3 shall include, in addition to the First Long Term Forecast, a forecast of Sankyo's purchases of the Drug Substance for delivery during the additional periods as described below. The chart below sets forth a schedule for the delivery of Long Term Forecasts of Sankyo's requirements of Drug Substance and describes what portion of each Long Term Forecast will constitute a firm commitment and what portion will be non-binding. These Long Term Forecasts shall be updated more frequently if deemed to be reasonably necessary by GelTex or Sankyo. The non-binding portion of each Long Term Forecast shall represent Sankyo's best estimate of its Drug Substance requirements from GelTex, and the non-binding portion of each Long Term Forecast shall be provided for the convenience of GelTex only, and shall not constitute firm purchase or shipping orders and shall not be binding upon, or create any obligation or liability with respect to Sankyo. With respect to all portions of a Long Term Forecasts designated as firm, Sankyo will be obligated to purchase at least [ * ] of the Drug Substance set forth in the firm forecast, and GelTex will not be obligated to supply purchase orders for more than [ * ] of the Drug Substance forecasted in the firm forecast. The schedule for forecasting under Sections 5.1.3 and 5.1.4 and the nature of each part of each forecast is set forth in table format below: Date Forecast Delivered Delivery Periods Nature of Forecast ----------------------- Covered by Forecast for Delivery Periods (the "Delivery Periods") -------------------- ------------------------ February 1, 2000 Feb. 2001-Dec. 31, 2001 [ * ] Jan. 1, 2002-Dec. 31, 2002 [ * ] Jan. 1, 2003-Dec. 31, 2003 [ * ] Jan. 1, 2004-Dec. 31, 2004 [ * ] Jan. 1, 2005-Dec. 31, 2005 [ * ] July 1, 2001 Jan. 1, 2002-Dec. 31, 2002 [ * ] Jan. 1, 2003-Dec. 31, 2003 [ * ] Jan. 1, 2004-Dec. 31, 2004 [ * ] Jan. 1, 2005-Dec. 31, 2005 [ * ] Jan. 1, 2006-Dec. 31, 2006 [ * ] Thereafter, Long Term Forecasts will continue to be delivered on July 1 of each year. In continuing with the schedule set forth above, each Long Term Forecast shall list the quantities of Drug Substance scheduled for delivery during the next calendar year. [ * ] In the event [ * ] Confidential information omitted and filed separately with the Commission 11 CONFIDENTIAL that the approval of the NDA for the Product is delayed substantially, the Parties may mutually agree to revise the forecasting sche...
Long Term Forecasts. No later than [***] ([***]) months after the Effective Date, Spectrum shall provide CyDex with a non-binding forecast setting forth Spectrum’s estimate of the required quantities of Clinical Grade Captisol for each of the following [***] ([***]) months. Such long-term forecast of Clinical Grade Captisol requirements shall thereafter be updated by Spectrum at least once every [***] ([***]) months. In addition, no later than [***] ([***]) months prior to the anticipated Commercial Launch Date by Spectrum or its Affiliates or Sublicensees of a Licensed Product in any particular country, Spectrum shall provide CyDex with a non-binding forecast setting forth Spectrum’s estimate of the required quantities of Commercial Grade Captisol for each of the following [***] ([***]) months. Such long-term forecast of Commercial Grade Captisol requirements shall thereafter be updated by Spectrum at least once every [***] ([***]) months.
Long Term Forecasts. Commencing on the Effective Date, each Customer will begin providing each Manufacturer on a monthly basis with rolling 12-month forecasts for projected volumes of Products (by SKU) for which such Customer expects to place Purchase Orders during the covered period (each, a “Long-Term Forecast”). The initial Long-Term Forecasts for RAI and Imperial are attached as Exhibits G-1 and G-2, respectively. Each subsequent Long-Term Forecast must be delivered at least five days before the first day of the first month of the covered 12-month period. Each Long-Term Forecast must be prepared for the relevant Products in a manner consistent with the practices used to forecast consumer demand for such Products for the 12-month period (approximated as necessary) ending immediately prior to the Effective Date, after giving effect to any production by the Customer in progressing towards a Manufacturing Migration or otherwise; provided that, a Customer may modify its practices for forecasting consumer demand for purposes of preparing its Long-Term Forecasts, subject to the approval of its Manufacturer, which approval may not be unreasonably withheld or delayed. Each Long-Term Forecast will be non-binding and will be used solely for general planning and inventory control purposes.
Long Term Forecasts. On a date to be agreed upon by the Parties following the Effective Date, but in any event such date to be no later than [***] months prior to estimated First Commercial Sale, and thereafter, prior to [***] of each Calendar Year during the Term, Licensee shall submit to TXMD a good faith estimate of the quantities of Product that Licensee expects to order from TXMD during the immediately following Calendar Year (“Long Term Forecast”). Subject to Section 6.6, Long Term Forecasts shall be non-binding.
Long Term Forecasts. During the Supply Term, SYNOVICS shall provide FAI with a rolling, good faith, non-binding forecast (by Calendar Quarter) of the quantity of each Products expected to be purchased, in the next year following the date of such forecast (with the first calendar year being the date on which such forecast is due), by SYNOVICS for the use in the development and manufacture of the Products. The first such forecast shall be submitted in writing to FAI no later than June 30, 2008 and thereafter updated forecasts shall be submitted to FAI no later than January 1 of each year.
Long Term Forecasts. Client will provide Catalent a long term forecast of its estimated purchases of Product ("Long Term Forecast"). Client shall provide to Catalent annual updates of the Long Term Forecast by [redacted]of each year, which updates shall cover each of the following [redacted]Years in the Term. Catalent will meet with Client annually to discuss available capacity to meet the Long Term Forecast.
Long Term Forecasts. Once commercial production of POC Rapid Assays is set to commence, SYN.X shall provide to PBM no later than 30 days before the first day of every calendar quarter during the Term of this Agreement, a rolling quarterly forecast of the quantities of POC Rapid Assays that SYN.X intends to order during the next four calendar quarters. Such forecasts shall represent the most current estimates for planning purposes, but shall not be purchase commitments.
